Perrigo gains FDA approval for Mucinex DM

Press enter to search
Close search
Open Menu

Perrigo gains FDA approval for Mucinex DM

By Michael Johnsen - 03/07/2018
Perrigo on Tuesday announced it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide extended-release tablets, 1200 mg/60 mg).

"This final approval and upcoming launch is an important accomplishment for our OTC business," Jeff Needham, executive vice president and president, Consumer Healthcare Americas, for Perrigo, said. "Key product launches like Perrigo's store brand equivalent of Mucinex® DM Maximum Strength provide our customers and consumers with high quality, value alternatives in important treatment categories."

Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Retail sales of the cough-cold product for the last 12 months were approximately $128 million as measured by IRI, Perrigo reported.

The company is finalizing plans to launch Perrigo's wholly owned store brand equivalent of Mucinex DM Maximum Strength for the 2018 cough-cold season.

This product will be packaged and marketed as a retailer own brand and will provide consumers with a value alternative to Mucinex DM Maximum Strength.